1-4 of 4
Daner Li, MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Geoffrey L. Uy, MD, John Godwin, MD, Michael P Rettig, PhD, Norbert Vey, Matthew Foster, Martha L. Arellano, MD, David A. Rizzieri, MD, Max S. Topp, MD, Gerwin Huls, MD PhD, Bob Lowenberg, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Helene Lelièvre, PhD PharmD, Ross La Motte-Mohs, PhD, Daner Li, MS, Jichao Sun, PhD, Kenneth Jacobs, MD, Karen Spohn, BS, Nadia Lonsdale, BA, Kathy Tran, Jan Baughman, MPH, Michele Shannon, PhD, Bernard Fox, PhD, Ezio Bonvini, MD, Jon Wigginton, Jan Davidson-Moncada, MD, John F DiPersio, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 637.
https://doi.org/10.1182/blood.V130.Suppl_1.637.637
Published: 2017
Journal Articles

Lead-in Dose Optimization to Mitigate Cytokine Release Syndrome in AML and MDS Patients Treated with Flotetuzumab, a CD123 x CD3 Dart® Molecule for T-Cell Redirected Therapy

Kenneth Jacobs, MD, John Godwin, MD, Matthew Foster, Norbert Vey, Geoffrey L. Uy, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Michael P Rettig, PhD, Stephanie Christ, MS, Max S. Topp, MD, Geert Huls, MD PhD, Bob Lowenberg, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Jichao Sun, PhD, Daner Li, MS, Kathy Tran, Karen Spohn, BS, Jan Baughman, MPH, Sadhna Shankar, MDMPH, Helene Lelièvre, PhD PharmD, Ezio Bonvini, MD, John F DiPersio, MD PhD, Jon Wigginton, Jan K davidson-Moncada, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3856.
https://doi.org/10.1182/blood.V130.Suppl_1.3856.3856
Published: 2017
Journal Articles

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Michael P Rettig, PhD, John Godwin, MD, Norbert Vey, Bernard Fox, PhD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Daner Li, MS, Daniel Primo, PhD, Joan Ballesteros, PhD, Jichao Sun, PhD, Helene Lelièvre, PhD PharmD, Jan Baughman, MPH, Ross La Motte-Mohs, PhD, John Muth, MS, Paul Moore, PhD, Ezio Bonvini, MD, Jon Wigginton, John F DiPersio, MD PhD, Jan Davidson-Moncada, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1365.
https://doi.org/10.1182/blood.V130.Suppl_1.1365.1365
Published: 2017
Journal Articles

Recruitment of Infants with Sickle Cell Anemia to a Phase III Trial:Data from the BABY HUG Study.

Lynn W Wynn, MSN, CPNP, Lane Faughnan, RN, BSN, CCRP, Daner Li, MS, Winfred Wang, MD, Brenda Martin, MSN, CPNP, Tracy Kelly, MSN, CPNP, Caroline Reed, MSN, FNP-C, Phillip Seaman, PA-C, Joan Marasciulo, RN, Elizabeth Rackoff, RN, BSN, Scott T. Miller, MD, Tally Hustace, ARNP, Glenda Thomas, RN, Jennifer Marshall, RN, ADN, Jennifer McDuffie, MSN, CRNP, MaryLou MacDermott, CRNP, Ellen Debenham, RN, CCRC, Mary Murphy, MSN, CNP, Renee C. Rees, PhD, for The BABY HUG Investigators
Journal: Blood
Blood (2008) 112 (11): 1429.
https://doi.org/10.1182/blood.V112.11.1429.1429
Published: 2008